Treatment of reactive perforating collagenosis with two forms of phosphodiesterase 4 inhibition
- 31 July 2025
- journal article
- case report
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (12) , 1575-1577
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Acquired Reactive Perforating CollagenosisNew England Journal of Medicine, 2023
- Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2023
- Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)The Lancet Regional Health - Europe, 2023
- Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigusNature Communications, 2023
- Reactive perforating collagenosis successfully treated with dupilumabAustralasian Journal of Dermatology, 2022
- Apremilast for the off-label treatment of lichenoid and interface dermatosesJournal of the American Academy of Dermatology, 2020
- Clinical practice guide for the treatment of perforating dermatosisThe Journal of Dermatology, 2020